Semaglutide shifted reward-based decision-making in people with depression
What was studied
Researchers used a computer task in which people choose between options with changing rewards, measuring how they balance sticking with the best-known option against exploring uncertain ones, processes thought to be altered in depression. Participants took oral semaglutide or placebo for 16 weeks and did the task before and after.
What was found
Semaglutide increased choosing the option with the highest expected reward, deliberate exploration of uncertain options, and repeating the previous choice. These effects were not explained by weight loss during the trial.
What it doesn’t tell us
Changes in a laboratory task are not changes in mood or daily life, and this analysis doesn’t report depression outcomes. The effects are small and the sample modest: it is a lead on how GLP-1 drugs may act on the brain, not evidence of benefit.